BBI Solutions launches two new SARS-Cov-2 antigens as raw materials for IVD manufacturers
BBI’s recently-acquired and well-respected team based in Freiburg, Germany (DIARECT GmbH) has developed two new recombinant antigen preparations produced in Baculovirus transfected Sf9 cells. The antigens Nucleocapsid (N) protein and Spike (S) glycoprotein Receptor Binding Domain (RBD) have been designed as critical raw materials for next generation serological assays. With the continuing COVID-19 vaccination programme, […]
